Barclays PLC Acquires 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

Barclays PLC boosted its position in Capricor Therapeutics Inc (NASDAQ:CAPR) by 106.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,296 shares of the biotechnology company’s stock after purchasing an additional 18,724 shares during the period. Barclays PLC’s holdings in Capricor Therapeutics were worth $552,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CAPR. State Street Corp grew its stake in Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after acquiring an additional 111,291 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Capricor Therapeutics in the 3rd quarter worth $3,806,000. PFM Health Sciences LP bought a new position in Capricor Therapeutics during the 3rd quarter worth approximately $2,324,000. Renaissance Technologies LLC boosted its position in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the period. Finally, Marshall Wace LLP purchased a new position in Capricor Therapeutics during the 2nd quarter valued at about $426,000. 21.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of research reports. Cantor Fitzgerald increased their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Maxim Group boosted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Oppenheimer reiterated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Piper Sandler began coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

NASDAQ:CAPR opened at $14.96 on Friday. The company has a market cap of $680.23 million, a price-to-earnings ratio of -14.11 and a beta of 3.98. The stock’s 50 day simple moving average is $16.82 and its two-hundred day simple moving average is $10.81. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.